Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapy

17 May 2025

Abstract excerpt

Immune-mediated protection generated to COVID-19 mRNA vaccines is associated with anti-Spike (S) protein neutralizing antibodies. However, humoral immunity is compromised in B cell depleting (BCD) therapies, used to treat autoimmune diseases such as Multiple Sclerosis (MS). To study the effect of BCD on the durability and protective efficacy of vaccine-induced immunity, we evaluated S-reactive antibodies and T...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune responses and vaccinations
Share to SARS-CoV-2 and COVID-19 Research
Share to Vaccine Coverage and Hesitancy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40382362
DOI: 10.1038/s41541-025-01151-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapyPMID 40382362Read ↗

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity Read ↗

Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapySemantic proximity Read ↗

B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent FeaturesSemantic proximity Read ↗

Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsSemantic proximity Read ↗

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity Read ↗

Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapySemantic proximity Read ↗

Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccinesSemantic proximity Read ↗

Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 VaccinationSemantic proximity Read ↗

T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapiesSemantic proximity Read ↗

Distinct Patterns of Humoral and Cellular Immune Responses Following SARS-CoV-2 mRNA Vaccination in Patients With Immune-Mediated Neurological Disorders on Anti-CD20 Therapy: A Prospective Cohort StudySemantic proximity Read ↗

Response to COVID-19 booster vaccinations in seronegative people with MSSemantic proximity Read ↗

The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.